CA3034956A1 - Treatment of nonalcoholic fatty liver disease - Google Patents

Treatment of nonalcoholic fatty liver disease Download PDF

Info

Publication number
CA3034956A1
CA3034956A1 CA3034956A CA3034956A CA3034956A1 CA 3034956 A1 CA3034956 A1 CA 3034956A1 CA 3034956 A CA3034956 A CA 3034956A CA 3034956 A CA3034956 A CA 3034956A CA 3034956 A1 CA3034956 A1 CA 3034956A1
Authority
CA
Canada
Prior art keywords
compound
dose
administered
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA3034956A
Other languages
English (en)
French (fr)
Other versions
CA3034956C (en
Inventor
Guido Hanauer
Hiroshi Nagabukuro
Yuichiro Amano
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda GmbH filed Critical Takeda GmbH
Publication of CA3034956A1 publication Critical patent/CA3034956A1/en
Application granted granted Critical
Publication of CA3034956C publication Critical patent/CA3034956C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA3034956A 2016-08-26 2017-08-25 TREATMENT OF NON-ALCOHOLIC HEPATIC STEATOSE Active CA3034956C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662380004P 2016-08-26 2016-08-26
US62/380,004 2016-08-26
PCT/EP2017/071418 WO2018037109A1 (en) 2016-08-26 2017-08-25 Treatment of nonalcoholic fatty liver disease

Publications (2)

Publication Number Publication Date
CA3034956A1 true CA3034956A1 (en) 2018-03-01
CA3034956C CA3034956C (en) 2024-10-29

Family

ID=59699703

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3034956A Active CA3034956C (en) 2016-08-26 2017-08-25 TREATMENT OF NON-ALCOHOLIC HEPATIC STEATOSE

Country Status (7)

Country Link
US (1) US11179384B2 (enExample)
EP (1) EP3503892A1 (enExample)
JP (1) JP7048863B2 (enExample)
CN (1) CN110099686B (enExample)
AU (1) AU2017317575B2 (enExample)
CA (1) CA3034956C (enExample)
WO (1) WO2018037109A1 (enExample)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004502643A (ja) 2000-02-16 2004-01-29 ユニバーシティ・オブ・ネブラスカ・メディカル・センター 線維症性疾患の治療法および治療用組成物
AU2005219576B2 (en) * 2004-03-03 2011-06-30 Takeda Gmbh Novel hydroxy-6-heteroarylphenanthridines and their use as PDE4 inhibitors
CN101133045A (zh) * 2005-03-02 2008-02-27 尼科梅德有限责任公司 6-杂环基取代的六氢菲啶衍生物的新盐类
NZ589278A (en) 2005-03-02 2012-04-27 Nycomed Gmbh Selected salts of 6-heterocyclyl substituted hexahydrophenanthridine derivatives
UA100497C2 (ru) * 2006-09-07 2013-01-10 Никомед Гмбх Комбинированное лечение сахарного диабета
WO2009109525A1 (en) * 2008-03-03 2009-09-11 Nycomed Gmbh Use of a specific pde4 inhibitor for the treatment and/or prophylaxis of non-alcoholic fatty liver disease
WO2009154230A1 (ja) * 2008-06-17 2009-12-23 持田製薬株式会社 非アルコール性脂肪肝炎の予防／改善・治療薬
US20160339010A1 (en) * 2014-01-22 2016-11-24 Takeda Gmbh Treatment of Partly Controlled or Uncontrolled Severe Asthma
US10300042B2 (en) * 2014-06-23 2019-05-28 Celgene Corporation Apremilast for the treatment of a liver disease or a liver function abnormality
JP2018521077A (ja) * 2015-07-29 2018-08-02 タケダ ゲー・エム・ベー・ハーＴａｋｅｄａ ＧｍｂＨ 糖尿病性腎症を治療するためのｐｄｅ４阻害剤

Also Published As

Publication number Publication date
EP3503892A1 (en) 2019-07-03
CA3034956C (en) 2024-10-29
JP2019524860A (ja) 2019-09-05
US11179384B2 (en) 2021-11-23
WO2018037109A1 (en) 2018-03-01
AU2017317575B2 (en) 2021-10-14
CN110099686A (zh) 2019-08-06
AU2017317575A1 (en) 2019-03-28
JP7048863B2 (ja) 2022-04-06
CN110099686B (zh) 2022-04-15
US20210283122A1 (en) 2021-09-16

Similar Documents

Publication Publication Date Title
US12171731B2 (en) Methods and compositions for the treatment of steatosis-associated disorders
RU2743075C2 (ru) Способы применения агонистов fxr
JP6941109B2 (ja) Ｆｘｒアゴニストを使用するための方法
KR101996245B1 (ko) 선택적 s1p1 수용체 아고니스트를 포함하는 약학 조합물
KR20180051561A (ko) 특정 환자 집단에서 신경퇴행성 장애를 치료하는 방법
JP2019530696A (ja) 線維性、硬変性の疾患もしくは障害を治療または予防するためのｆｘｒアゴニストを含む組合せ組成物
KR20190044667A (ko) Fxr 작용제의 신규 요법
AU2015231076B2 (en) Carboxy-cyclopropyl undecanol compounds for treatment of liver disease and other medical disorders
CN114096257A (zh) 包含如sglt 1/2抑制剂的sglt抑制剂的治疗
AU2022282651A1 (en) Pemafibrate and/or tofogliflozin for use in treating liver disease
CA3034956C (en) TREATMENT OF NON-ALCOHOLIC HEPATIC STEATOSE
US20220313622A1 (en) Phytocannabinoids for preventing or treating non-alcoholic fatty liver disease, dyslipidemia, and type 2 diabetes
US20190161483A1 (en) Methods for using fxr agonists
WO2007127913A2 (en) Reducing risk of type 2 diabetes (t2d)
HK40012462A (en) Treatment of nonalcoholic fatty liver disease
HK40012462B (en) Treatment of nonalcoholic fatty liver disease
EP4166137B1 (en) Therapeutic agent for fatty liver disease
TWI906348B (zh) 脂肪性肝疾病之治療劑
HK40080642A (en) Therapeutic agent for fatty liver disease
HK40089150B (en) Therapeutic agent for fatty liver disease
BR112020004903A2 (pt) uso de anticorpos de ligação de il-1b para o tratamento de hepatite alcoólica

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220325

EEER Examination request

Effective date: 20220325

EEER Examination request

Effective date: 20220325

EEER Examination request

Effective date: 20220325

EEER Examination request

Effective date: 20220325

EEER Examination request

Effective date: 20220325

EEER Examination request

Effective date: 20220325

EEER Examination request

Effective date: 20220325